Difference between revisions of "Goserelin (Zoladex)"
Jump to navigation
Jump to search
m (added package insert, links) |
m |
||
| (11 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesis<ref name="insert">[http://documents.tersera.com/zoladex-us/10.8mg_MagnumPI.pdf Goserelin (Zoladex) package insert]</ref><ref>[[ | + | Class/mechanism: Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesis<ref name="insert">[http://documents.tersera.com/zoladex-us/10.8mg_MagnumPI.pdf Goserelin (Zoladex) package insert]</ref><ref>[[:File:Goserelin.pdf | Goserelin (Zoladex) package insert (locally hosted backup)]]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 16: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 12 | + | * 1989-12-29: Initial FDA approval for palliative treatment of advanced [[prostate cancer|carcinoma of the prostate]]. ''(Based on Pilepich et al. 1995)'' |
| + | ==History of changes in EMA indication== | ||
| + | ''The approval of this drug pre-dates the EMA.'' | ||
| + | *1987-05-12: EURD | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2014-03-17: New additional indication for the treatment of premenopausal [[breast cancer]]. | ||
==Also known as== | ==Also known as== | ||
| + | *'''Generic name:''' goserelin acetate | ||
*'''Brand names:''' Novgos, Zoladex | *'''Brand names:''' Novgos, Zoladex | ||
| Line 32: | Line 38: | ||
[[Category:FDA approved in 1989]] | [[Category:FDA approved in 1989]] | ||
| + | [[Category:EMA approved in 1987]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 18:34, 13 June 2023
General information
Class/mechanism: Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesis[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Patient counseling information can be found in the package insert[1]
- Goserelin (Zoladex) patient drug information (Chemocare)[3]
- Goserelin (Zoladex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1989-12-29: Initial FDA approval for palliative treatment of advanced carcinoma of the prostate. (Based on Pilepich et al. 1995)
History of changes in EMA indication
The approval of this drug pre-dates the EMA.
- 1987-05-12: EURD
History of changes in PMDA indication
- 2014-03-17: New additional indication for the treatment of premenopausal breast cancer.
Also known as
- Generic name: goserelin acetate
- Brand names: Novgos, Zoladex